Who is sponsoring NCT03462784?

NCT03462784 is sponsored by Assiut University.

What drugs are being tested in NCT03462784?

Interventions in NCT03462784: Demographic, physical examination, data will becollected ..

What condition does NCT03462784 study?

NCT03462784 studies Beta-thalassemia.

Is NCT03462784 still recruiting?

NCT03462784 is currently status unknown. Last updated 18 January 2020.

Last reviewed 2020-01-18 · How we verify

NCT03462784

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Complications in Children With B- Thalassemia Major

Status unknown Last updated 18 January 2020

What this trial tests

trial testing Demographic, physical examination, data will becollected . in Beta-thalassemia in 201 participants. Status unknown.

Timeline

1 August 2020

Primary endpoint
1 October 2020

1 December 2020

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	201
Start date	1 August 2020
Primary completion	1 October 2020
Estimated completion	1 December 2020

Drugs / interventions tested

Demographic, physical examination, data will becollected .

Conditions studied

Beta-thalassemia — all drugs for Beta-thalassemia →

Sponsor

Assiut University

Who can join

Adults 1 to 18, any sex, with Beta-thalassemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Worldwide, there are more than 60,000 births annually of serious forms of thalassemia .The World Health Organization considers thalassemia to be a major health burden. Beta- thalassemia is a group of recessively inherited disorders of hemoglobin synthesis characterized by reduced synthesis of the ß-globin chain caused by a mutation. The homozygous state results in severe anemia which needs regular blood transfusion.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Beta-thalassemia

Currently open trials in the same condition.

NCT05567458 — A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due t · Phase 2 · active not recruiting
NCT04064060 — A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Tria · Phase 3 · recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03462784 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 18 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03462784.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing